Evotec Investor Day Presentation Deck

evotec BAYER PAGE 59 BAYER Start: 2016 • Strong pipeline • Financials - UF payment: ND - Research funding - MS of > € 300 m - Tiered royalties Molecular patient databases translate to high value partnerships Partnerships deliver significant cash flow and upside evotec V VIFOR PHARMA Start: 2019 • Multiple projects • Financials evotec Neph Thera Funding of € 25 m • Evotec owns 50% of Neph Thera novo nordisk evotec Start: 2020 • Pipeline building initiated • Financials - UF payment: ND - Research funding - MS of > € 150 m / per product - Tiered royalties

View entire presentation